Commitments and Contingencies |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Commitments and Contingencies Disclosure [Abstract] | |
| Commitments and Contingencies |
16. Commitments and Contingencies
Partnership Advance
On July 14, 2025, the Company expanded its partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. The expansion included a $1 million advance from STADA to the Company in non-dilutive capital to support product launches and marketing efforts under the Master Distribution Agreement between the parties and relates to the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks. As of September 30, 2026 and December 31, 2025, the Company held $380 thousand and $741 thousand, respectively, of restricted cash related to advances received under partnership arrangements. Correspondingly, $359 thousand and $731 thousand, respectively, were recorded as current liabilities within partnership accrued advances. The advance is subject to contractual restrictions on use and will be applied against eligible project costs as incurred in accordance with the terms of the Master Distribution Agreement, as amended.
License agreement
Under the License Agreement described in Note 1, the Company may be required to make contingent milestone payments of up to $20.0 million to Celularity upon the achievement of specified commercial milestones. No amounts have been recorded due to the uncertainty regarding the achievement of the applicable milestones.
Litigation
Except as described below, the Company may be subject to legal proceedings and claims that arise in the ordinary course of business. Management is not currently aware of any matters that will or may have a material effect on the financial position, results of operations, or cash flows of the Company.
On April 27, 2026, Bezalel Partners, LLC (“Bezalel”) commenced an arbitration proceeding against the Company before JAMS, asserting claims for breach of contract and declaratory relief arising from a Finder’s Fee Agreement, dated July 29, 2024, as amended. Bezalel alleges that it is entitled to a “Transaction Fee” in excess of $1,750 thousand, plus interest, attorneys’ fees and costs. On July 2, 2026, the Company filed its Answer, denying Bezalel’s claims in their entirety and asserting affirmative defenses. The Company intends to vigorously defend against this claim. Given the early stage of this proceeding, the Company is unable to predict its outcome, hearing or resolution timing or estimate a range of reasonably possible loss, if any, at this time.
On September 15, 2026, the Company’s former President and Chief Executive Officer, who was also a former member of the Company’s Board of Directors, filed a complaint against the Company in the United States District Court for the Southern District of New York. The complaint alleges breach of his Executive Employment Agreement and certain other allegations in connection with the termination of his employment effective August 21, 2026. The Company disputes the plaintiff’s claims and intends to defend the action vigorously. As of September 30, 2026, the Company had accrued $375 thousand related to this matter. The accrual is not an admission of liability. The Company is unable to estimate any reasonably possible loss in excess of the amount accrued. Litigation is inherently uncertain.
|